We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-1.06%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$716M
AUM Growth
-$19.1M
Cap. Flow
+$8.71M
Cap. Flow %
1.22%
Top 10 Hldgs %
27.06%
Holding
107
New
3
Increased
17
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$11.4M
2
VCYT icon
Veracyte
VCYT
+$10M
3
LOW icon
Lowe's Companies
LOW
+$3.19M
4
CPN
Calpine Corporation
CPN
+$2.73M
5
LYB icon
LyondellBasell Industries
LYB
+$2.16M

Top Sells

Rank Stock Value
1
ROC
ROCKWOOD HLDGS INC
ROC
+$12.9M
2
SDRL
Seadrill Limited Common Stock
SDRL
+$9.17M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.54M
4
UFS
DOMTAR CORPORATION (New)
UFS
+$2.29M
5
SZYM
SOLAZYME INC COM STK (DE)
SZYM
+$1.82M

Sector Composition

Rank Sector Weight
1 Healthcare 29.21%
2 Technology 14.59%
3 Consumer Discretionary 13.52%
4 Industrials 8.55%
5 Energy 5.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
76
Arrowhead Research
ARWR
$12.3B
$1.69M 0.24%
114,700
+34,700
+43% +$474K
CEMP
77
DELISTED
Cempra, Inc.
CEMP
$1.69M 0.24%
153,800
– –
SAAS
78
DELISTED
inContact, Inc.
SAAS
$1.68M 0.23%
193,300
– –
TGTX icon
79
TG Therapeutics
TGTX
$8.19B
$1.65M 0.23%
155,000
+20,000
+15% +$185K
NBIX icon
80
Neurocrine Biosciences
NBIX
$18.7B
$1.51M 0.21%
96,600
– –
ATHN
81
DELISTED
Athenahealth, Inc.
ATHN
$1.46M 0.2%
11,100
– –
SZYM
82
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
$1.42M 0.2%
190,000
-194,400
-51% -$1.82M
LITS
83
Lite Strategy Inc
LITS
$33.6M
$1.39M 0.19%
10,080
– –
BRKR icon
84
Bruker
BRKR
$9.79B
$1.37M 0.19%
73,900
– –
PCRX icon
85
Pacira BioSciences
PCRX
$1.06B
$1.29M 0.18%
13,300
– –
SAGE
86
DELISTED
Sage Therapeutics
SAGE
$1.27M 0.18%
+40,200
New +$1.16M
CSII
87
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.25M 0.17%
52,700
– –
INSM icon
88
Insmed
INSM
$22B
$1.16M 0.16%
88,600
– –
FEIC
89
DELISTED
FEI COMPANY
FEIC
$1.12M 0.16%
14,800
– –
TNDM icon
90
Tandem Diabetes Care
TNDM
$1.3B
$1.07M 0.15%
+8,000
New +$1.12M
KPTI icon
91
Karyopharm Therapeutics
KPTI
$159M
$1.05M 0.15%
2,000
– –
OMED
92
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1M 0.14%
52,800
– –
MDSO
93
DELISTED
Medidata Solutions, Inc.
MDSO
$837K 0.12%
18,900
– –
DRNA
94
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$811K 0.11%
63,700
– –
TLPH icon
95
Talphera
TLPH
$70.1M
$765K 0.11%
6,970
– –
XOMA
96
DELISTED
Xoma
XOMA
$746K 0.1%
8,860
– –
ADVM
97
DELISTED
Adverum Biotechnologies
ADVM
$684K 0.1%
+2,000
New +$595K
AEGR
98
DELISTED
Aegerion Pharmaceuticals
AEGR
$668K 0.09%
20,000
– –
VIRX
99
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$655K 0.09%
437
– –
TFX icon
100
Teleflex
TFX
$5.86B
$609K 0.09%
5,800
– –
1 2 3
4
5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Eventide Asset Management held 107 positions worth $716M, down 2.6% from $735M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management's Q3 2014 filing shows 3 new, 17 increased, 4 reduced and 4 closed positions. Its largest new stake was Sage Therapeutics: 40,200 shares worth $1.27M. The largest sale was ROCKWOOD HLDGS INC, an estimated $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 27% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q3 2014 buy was Sage Therapeutics: 40,200 shares worth $1.27M.
  • Eventide Asset Management added most to bluebird bio in Q3 2014, an estimated $11.4M increase.
  • Eventide Asset Management's biggest Q3 2014 reduction was Agios Pharmaceuticals, cutting an estimated $2.54M.
  • Eventide Asset Management fully exited ROCKWOOD HLDGS INC in Q3 2014, selling an estimated $12.9M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $716M portfolio in Q3 2014.
  • Eventide Asset Management opened 3 new positions and closed 4 in Q3 2014.
  • Eventide Asset Management's portfolio value fell 2.6% quarter-over-quarter to $716M.

Based on Eventide Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.